https://www.biopharmawatch.com/news/DTIL/precision-biosciences-dosing-phase-1-2-function-dmd-study BiopharmaWatch en 2026-08-24T10:01:00.000Z Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study https://www.biopharmawatch.com/news/OCS/first-patient-treated-pioneer-1-trial-privosegtor-optic-neuritis BiopharmaWatch en 2026-08-24T08:00:00.000Z First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-08-24 BiopharmaWatch en 2026-08-24T07:15:32.636Z Biotech Catalysts to Watch: Key Developments for Q4 2026 https://www.biopharmawatch.com/news/ACAD/european-commission-approves-daybu-trofinetide-rett-syndrome BiopharmaWatch en 2026-08-24T07:01:00.000Z European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union https://www.biopharmawatch.com/news/ACAD/daybu-approval-rett-syndrome-eu BiopharmaWatch en 2026-08-24T07:01:00.000Z De Europese Commissie keurt DAYBU® (trofinetide) goed als eerste en enige behandeling voor neurologische gedragssymptomen van het Rett-syndroom in de Europese Unie https://www.biopharmawatch.com/news/TAK/orzeiful-oveporexton-approval-japan-narcolepsy BiopharmaWatch en 2026-08-24T06:36:00.000Z ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 https://www.biopharmawatch.com/news/VNDA/nereus-sponsor-no-47-indycar-freedom-250-grand-prix BiopharmaWatch en 2026-08-22T19:16:00.000Z NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.